ORGENESIS INC (ORGS) Stock Price, Quote, News and Overview
NASDAQ:ORGS - Nasdaq - US68619K2042 - Common Stock - Currency: USD
ORGS Quote, Performance and Key Statistics
2.11
-1.13 (-34.84%)
The current stock price of ORGS is 2.11 USD. In the past month the price decreased by -59.22%. In the past year, price decreased by -76.89%.
ORGS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ORGS
Company Profile
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 146 full-time employees. The company went IPO on 2010-07-01. The firm focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. The company operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Company Info
ORGENESIS INC
20271 Goldenrod Lane
Germantown MARYLAND 20876 US
CEO: Vered Caplan
Employees: 146
Company Website: https://www.orgenesis.com/
Phone: 14806596404
ORGENESIS INC / ORGS FAQ
What is the stock price of ORGENESIS INC today?
The current stock price of ORGS is 2.11 USD. The price decreased by -34.84% in the last trading session.
What is the ticker symbol for ORGENESIS INC stock?
The exchange symbol of ORGENESIS INC is ORGS and it is listed on the Nasdaq exchange.
On which exchange is ORGS stock listed?
ORGS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORGENESIS INC stock?
7 analysts have analysed ORGS and the average price target is 6.12 USD. This implies a price increase of 190.05% is expected in the next year compared to the current price of 2.11. Check the ORGENESIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORGENESIS INC worth?
ORGENESIS INC (ORGS) has a market capitalization of 10.06M USD. This makes ORGS a Nano Cap stock.
How many employees does ORGENESIS INC have?
ORGENESIS INC (ORGS) currently has 146 employees.
Is ORGENESIS INC (ORGS) expected to grow?
The Revenue of ORGENESIS INC (ORGS) is expected to grow by 39.76% in the next year. Check the estimates tab for more information on the ORGS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORGENESIS INC (ORGS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORGS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORGS, evaluating the profitability, health, valuation and growth aspects
- ORGENESIS INC (ORGS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORGENESIS INC (ORGS) Sales and EPS estimates to see what analysts future expectations are.
- ORGENESIS INC (ORGS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORGENESIS INC (ORGS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORGENESIS INC (ORGS) Stock Chart to make your own analysis
- ORGENESIS INC (ORGS) Latest news and press-releases to stay up to date.
Does ORGENESIS INC (ORGS) stock pay dividends?
ORGS does not pay a dividend.
When does ORGENESIS INC (ORGS) report earnings?
ORGENESIS INC (ORGS) will report earnings on 2024-11-11, before the market open.
What is the Price/Earnings (PE) ratio of ORGENESIS INC (ORGS)?
ORGENESIS INC (ORGS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of ORGENESIS INC (ORGS) stock?
The outstanding short interest for ORGENESIS INC (ORGS) is 0.47% of its float. Check the ownership tab for more information on the ORGS short interest.
ORGS Technical Analysis
ORGS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ORGS. ORGS has a bad profitability rating. Also its financial health evaluation is rather negative.
ORGS Financial Highlights
Over the last trailing twelve months ORGS reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by -125.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ORGS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ORGS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 190.48% and a revenue growth 39.76% for ORGS